Phase III trial of NLX P101 in patients with Parkinson's disease.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NLX P101 (Primary)
Indications Parkinson's disease
Focus Registrational; Therapeutic Use
Sponsors Neurologix

Most Recent Events

11 Aug 2022 According to a MeiraGTx media release, company expects to initiate enrollment in this study during the second half of 2022 with material manufactured in its cGMP facility in London, United Kingdom.
16 Mar 2011 Trial is still being planned.
07 May 2008 New trial record.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight